JeyanthiRamanarayananMD

Medical Oncologist, St Joseph's/Candler Health System

Dr. Ramanarayanan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University at BuffaloFellowship, Hematology and Medical Oncology, 2003 - 2005
University at BuffaloFellowship, Hematology and Medical Oncology, 2001 - 2003
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1998 - 2001
Sri Ramachandra Medical CollegeClass of 1995

PubMed

6 citations
Targeted treatment of chronic myeloid leukemia: role of imatinib
Ila Tamascar, Jeyanthi Ramanarayanan
Oncotargets and Therapy. 2009-02-18
11 citations
BCNU toxicity presenting with a large pericardial and pleural effusion.
Ganapathy S. Krishnan, Vijay Chaudhary, Anas Al-Janadi, Jeyanthi Ramanarayanan, Karl J. D’Silva
Annals of Transplantation. 2008-03-28
33 citations
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
Jeyanthi Ramanarayanan, Francisco J. Hernandez-Ilizaliturri, Asher Chanan-Khan, Myron S. Czuczman
British Journal of Haematology. 2004-12-01

Journal Articles

Immunotherapy in Early Stage Non-Small Cell Lung Cancer. Advancer in Lung Cancer.(2022) Vol 11, 331-44.
Jeyanthi Ramanarayanan, Ganapathy Krishnan, Advances in Lung Cancer

Books/Book Chapters

Medicine and Medical Research: New Perspectives Vol. 3, 22 August 2024 , Page 30-44
Chapter: Advancements in Tyrosine Kinase Inhibitors Therapy: Role of Imatinib, the First Targeted Treatment for Chronic Myeloid Leukemia
Page 30 - 44Jeyanthi RamanarayananBP International2024